Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Halfan
Halofantrine is an antimalarial drug used to treat acute, uncomplicated malaria caused by *Plasmodium falciparum*, including chloroquine-resistant strains. It belongs to the class of arylmethanol antimalarials and acts by inhibiting heme polymerization within the parasite, disrupting its life cycle. Due to its potential for cardiotoxicity, especially at higher doses or with repeated administration, its use is restricted and generally reserved for areas where resistance to other antimalarials is prevalent.
For the treatment of acute, uncomplicated malaria caused by Plasmodium falciparum, especially chloroquine-resistant strains.
Halofantrine can cause serious and potentially fatal cardiac arrhythmias, including QT prolongation. It should not be used in patients with pre-existing cardiac conditions or those taking medications that prolong the QT interval. ECG monitoring is recommended.
Outcome:
Increased risk of cardiotoxicity
Mechanism:
Additive QT prolongation
Outcome:
Potential for reduced efficacy of both drugs
Mechanism:
Unknown
Outcome:
Increased halofantrine absorption
Mechanism:
Enhanced solubility
Most likely new formulation: Combination therapy with a safer antimalarial (Year: 2026, 30% confidence)
Based on reported cardiotoxicity events, there is a low ( <1%) likelihood of new restrictions on halofantrine use in the next 5 years.
Antimalarial
Arylmethanol